July 2, 2018
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

TREAKISYM® Receives Approval for Combined Use withAnti-CD20 Antibodies

TOKYO, Japan, July 2, 2018 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, Japan;
hereinafter referred to as "SymBio") announced today that it has obtained approval for a partialchange to its marketing authorization for the anti-cancer agent TREAKISYM® (non-proprietary
name: bendamustine hydrochloride).
In Europe and the United States, a significant number of new anti-CD20 antibodies (*1) are being
developed for treatment of low-grade B-cell non-Hodgkin's lymphoma (low-grade NHL). The approval
permits the use of TREAKISYM® in combination with rituximab or other new anti-CD20 antibodies
and will expand the treatment options available to patients.
Today, Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo) obtained marketing approval forGAZYVA® (non-proprietary name: obinutuzumab) (*2) for CD20 positive follicular lymphoma, a typical
histologic type of low-grade NHL. After the launch of GAZYVA®, the approval will allow the combined
use of TREAKISYM® and GAZYVA® for the treatment of CD20 positive follicular lymphoma.
In Japan, the market share for TREAKISYM® in the field of first-line treatrment of low-grade NHL is
now more than 50%, as TREAKISYM® has steadily replaced the conventional standard therapy, RCHOP. The approval for combination use with anti-CD20 antibodies will benefit patients with newtreatment options and strengthen the position of TREAKISYM® as a standard therapy for thetreatment of malignant lymphoma, further expanding SymBio’s business and enhancing its
enterprise value.
There is no change to the Company’s earnings forecast for the year ended December 31, 2018.

1

(*1) CD20 is a transmembrane phosphoprotein that is a surface-membrane molecule specifically
expressed on lymphocyte B cells. Anti-CD20 antibodies recognize and bind to CD20 in vivo, and target
the binding to kill B cells by natural killer cells.
(*2) Refer to the Chugai Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. press release
relating to GAZYVA® (non-proprietary name: obinutuzumab) dated July 2, 2018.
https://www.chugai-pharm.co.jp/english/news/detail/20180702150000.html[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About TREAKISYM®
TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug firstused in Germany in the 1970s, is now widely used in more than 50 countries with indications for lowgrade non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.
TREAKISYM® Intravenous Infusion 100 mg was approved in October, 2010 for manufacturingand marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma
and mantle cell lymphoma in Japan.

TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia inJapan in August, 2016.

TREAKISYM® Intravenous Infusion 25 mg, a standard low-dose product, was approved for
manufacturing and marketing in Japan in September, 2016.



TREAKISYM® was approved for the additional indication of first-line treatment of low-grade Bcell non-Hodgkin’s lymphoma and mantle cell lymphoma in Japan in December, 2016.

TREAKISYM® has been marketed by SymBio through its partnership with Eisai Co., Ltd. sinceDecember, 2010.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May, 2016 SymBio incorporated its wholly-owned subsidiary in the U.S., called SymBio
Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida).
SymBio’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to be aleading global specialty biopharmaceutical company dedicated to addressing underserved medical
needs with main therapeutic focus in oncology, hematology and pain management.

2